β1-adrenergic receptors polymorphisms and left ventricular remodeling changes in response to β-blocker therapy

Pharmacogenetics and Genomics

Volumn 15, Issue 4, 2005, Pages 227-234

  Terra, Steven G ^a   Hamilton, Karen K ^b   Pauly, Daniel F ^b   Lee, Craig R ^d   Patterson, J Herbert ^d,e   Adams, Kirkwood F ^e   Schofield, Richard S ^b,f   Belgado, Bernadette S ^a   Hill, James A ^b   Aranda, Juan M ^b   Yarandi, Hossein N ^c   Johnson, Julie A ^a,b  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF FLORIDA   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

^e UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^f VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Ejection fraction; Left ventricular remodeling; Pharmacogenomics; blocker

Indexed keywords

ANTITHROMBOCYTIC AGENT; ARGININE; BETA 1 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; FUROSEMIDE; GLYCINE; METOPROLOL; SERINE; SPIRONOLACTONE; ADRENERGIC RECEPTOR;

ADRENERGIC SYSTEM; ADULT; AGED; ARTICLE; CODON; DOSE TIME EFFECT RELATION; ECHOCARDIOGRAPHY; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HEART FAILURE; HEART LEFT VENTRICLE; HEART VENTRICLE FUNCTION; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MULTIPLE REGRESSION; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECEPTOR GENE; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE; CONGESTIVE HEART FAILURE; DRUG EFFECT; GENETICS; HEART VENTRICLE; HEART VENTRICLE REMODELING; HOMOZYGOTE; METABOLISM; MIDDLE AGED; PATHOLOGY; PHARMACOGENETICS; REGRESSION ANALYSIS; SYSTOLE; TIME;

ADRENERGIC BETA-ANTAGONISTS; CODON; ECHOCARDIOGRAPHY; FEMALE; GENOTYPE; HEART FAILURE, CONGESTIVE; HEART VENTRICLES; HETEROZYGOTE; HOMOZYGOTE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PHARMACOGENETICS; POLYMORPHISM, GENETIC; RECEPTORS, ADRENERGIC; RECEPTORS, ADRENERGIC, BETA-1; REGRESSION ANALYSIS; SYSTOLE; TIME FACTORS; VENTRICULAR REMODELING;

EID: 20244371488     PISSN: 17446872     EISSN: None     Source Type: Journal    
DOI: 10.1097/01213011-200504000-00006     Document Type: Article

References (32)

1. Jessup M, Brozena S. Heart failure. N Engl J Med 2003; 348:2007-2018.
2. Hall SA, Cigarroa CG, Marcoux L, Risser RC, Grayburn PA, Eichhorn EI. Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade. J Am Coll Cardiol 1995; 25:1154-1161.
3. Lowes BD, Gill EA, Abraham WT, Larrain JR, Robertson AD, Bristow MR, et al. Effects of carvedilol on left ventricular mass, chamber geometry, and mitral regurgitation in chronic heart failure. Am J Cardiol 1999; 83:1201-1205.
4. Udelson JE, Konstam MA. Relation between left ventricular remodeling and clinical outcomes in heart failure patients with left ventricular systolic dysfunction. J Card Fail 2002; 8:3465-3471.
5. Doughty RN, Whalley GA, Gamble G, MacMahon S, Sharpe N. Left ventricular remodeling with carvedilol in patienta with congestive heart failure due to ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group. J Am Coll Cardiol 1997; 29:1060-1066.
6. MERIT-HF Study Group. Effects of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353:2001-2007.
7. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999; 353:9-13.
8. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, et al. Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001; 344:1651-1658.
9. Hunt SA, Baker DW, Chin MH, Cinquegrani MP, Feldman AM, Francis GS, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2001; 38:2101-2113.
10. Metra M, Giubbini R, Nodari S, Boldi E, Modena MG, Dei Cas L. Differential effects of β-blockers in patients with heart failure. Circulation 2000; 102:546-551.
11. Johnson JA, Zineh I, Puckett BJ, McGorray SP, Yarandi HN, Pauly DF, Beta 1-adrenergic receptor polymorphisms and antlhypertensive response to metoprolol. Clin Pharmacol Ther 2003; 74:44-52.
12. Maqbool A, Hall AS, Ball SG, Balmforth AJ. Common polymorphisms of beta1-adrenoceptor: identification and rapid screening assay (letter). Lancet 1999; 353:897.
13. Mason DA, Moore JD, Green SA, Liggett SB. A gain-of-function polymorphism in a G-protein coupling domain of the human β1-adrenergic receptor. J Biol Chem 1999; 274:12670-12674.
14. Mialet Perez J, Rathz DA, Petrashevskaya NN, Hahn HS, Wagoner LE, Schwartz A, et al. Beta 1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure. Nat Med 2003; 9:1300-1305.
15. Levin MC, Marullo S, Muntaner O, Andersson B, Magnusson Y. The myocardium-protective Gly-49 variant of the β1-adrenergic receptor exhibits constitutive activity and increased desensitization and down-regulation. J Biol Chem 2002; 277:30429-30435.
16. Terra SG, McGorray SP, Wallace MR, Picoult-Newberg L, Repine CJ, Johnson JA. Beta1-adrenergic receptor polymorphisms and linkage disequilibrium (abstr). Clin Pharmacol Ther 2002; 71:70.
17. Moore JD, Mason DA, Green SA, Hsu J, Liggett SB. Racial differences in the frequencies of cardiac β1-adrenergic receptor polymorphisms: analysis of c145A>G and c1165G>C. Hum Mutat 1999; 14:271.
18. Borjesson M, Magnusson Y, Hjalmarson Y, Andersson B. A novel polymorphism in the gene coding for the beta(1)-adrenergic receptor associated with survival in patients with heart failure. Eur Heart J 2000; 21:1853-1858.
19. Konstam MA, Udelson JE, Anand IS, Cohn JN. Ventricular remodeling in heart failure: a credible surrogate endpoint. J Card Fail 2003; 9: 350-353.
20. Metra M, Nodari S, Parrinello G, Giubbini R, Manca C, Dei Cas L. Marked improvement in left ventricular ejection fraction during long-term β-blockade in patients with chronic heart failure; clinical correlates and prognostic significance. Am Heart J 2003; 145:292-299.
21. Lechat P, Hulot JS, Escolano S, Mallet A, Leizorovicz A, Werhlen-Grandjean M, et al. Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II trial. Circulation 2001; 103: 1428-1433.
22. Packer M, Antonopoulos GV, Berlin JA, Chittams J, Konstam MA, Udelson JE. Comparative effects of carvedilol and metoprolol on left ventricular ejection fraction in heart failure: results of a meta-analysis. Am Heart J 2001; 141:899-907.
23. Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, et al. Carvedilol or Metoprolol European Trial Investigators. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003; 362:7-13.
24. La Rovere MT, Pinna GD, Maestri R, Mortara A, Capomolla S, Febo O, et al. Short-term heart rate variability strongly predicts sudden cardiac death in chronic heart failure patients. Circulation 2003; 107:565-570.
25. White HL, de Boer RA, Maqbool A, Greenwood D, van Veldhuisen DJ, Cuthbert R, et al. on behalf of the MERIT-HF Study Group. An evaluation of the beta-1 adrenergic receptor Arg389Gly polymorphism in individuals with heart failure: a MERIT-HF sub-study. Eur J Heart Fail 2003; 5:463-468.
26. Beta-Blocker Evaluation of Survival Trial Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 2001; 344:1659-1687.
27. Kaye DM, Smirk B, Williams C, Jennings G, Esler M, Holst D. Beta-adrenoceptor genotype influences the response to carvedilol in patients with congestive heart failure. Pharmacogenetics 2003; 13:379-382.
28. Sofowora GG, Dishy V, Muszkat M, Xie HG, Kim RB, Harris PA, et al. A common beta1-adrenergic receptor polymorphism (Arg389Gly) affects blood pressure response to beta-blockade. Clin Pharmacol Ther 2003; 73:366-371.
29. Liu J, Liu ZQ, Tan ZR, Chen XP, Wang LS, Zhou G, Zhou HH. Gly389Arg polymorphism of beta1-adrenergic receptor is associated with the cardiovascular response to metoprolol. Clin Pharmacol Ther 2003; 74: 372-379.
30. Adams KF Jr. Which beta-blocker for heart failure? Am Heart J 2001; 141:884-888.
31. Terra SG, Pauly DF, Lee CR, Patterson JH, Adams KF, Schofield RS, et al. Beta-adrenergic receptor polymorphisms and responses during titration of metoprolol CR/XL in heart failure. Clin Pharamacol Ther in press.
32. Dubach P, Myers J, Bonetti P, Schertler T, Froelicher V, Wagner D, et al. Effects of bisoprolol fumarate on left ventricular size, function, and exercise capacity in patients with heart failure: analysis with magnetic resonance myocardial tagging. Am Heart J 2002; 143:676-683.